Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women

A. Sapino, L. Righi, P. Cassoni, M. Papotti, P. Gugliotta, G. Bussolati

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Neuroendocrine (NE) breast carcinomas are a rare entity in young women; however, their frequency increases in aged patients. The present work demonstrates that NE breast carcinomas in elderly women can also express an apocrine immunophenotype and analyzes the histological and clinical aspects of such differentiation. A selected series of 50 NE tumors (positive for NE markers in ≥50% of the cells) was tested for the immunocytochemical expression of gross cystic disease fluid protein-15 (GCDFP-15). The results demonstrated that about 50% of moderately (G2) and well-differentiated (G1) NE breast carcinomas (mucinous, solid papillary, and solid cohesive histotypes) coexpressed the apocrine marker. In these cases, specific mRNA for GCDFP-15 (PIP) and for chromogranin A (ChA) was demonstrated using in situ hybridization (ISH). Carcinomas of the alveolar subtype (G2) and poorly differentiated carcinomas (G3), including one case of atypical carcinoid, were pure NE carcinomas, devoid of apocrine differentiation. The steroid receptor status of these lesions was evaluated to test a possible involvement of androgen receptors in apocrine differentiation. We demonstrated that the level of AR and the mean age of patients at diagnosis were significantly higher in apocrine than in non-apocrine differentiated tumors. The histological grade and the expression of estrogen receptor (ER) significantly influenced the prognosis of these NE carcinomas, either pure or NE-apocrine differentiated. The most original result of our study is therefore the demonstration of a possible divergent apocrine differentiation of NE breast carcinomas that might be regulated by the activation of androgen receptors in elder patients. In addition, the possibility for using Chs or GCDFP-15 serum values in the follow-up of these patients, as demonstrated in two cases of the present series, can justify the immunophenotyping of the tumors.

Original languageEnglish
Pages (from-to)768-776
Number of pages9
JournalModern Pathology
Volume14
Issue number8
DOIs
Publication statusPublished - 2001

Fingerprint

Neuroendocrine Carcinoma
Differentiation Antigens
Breast Neoplasms
Androgen Receptors
Bronchiolo-Alveolar Adenocarcinoma
Chromogranin A
Immunophenotyping
Neuroendocrine Tumors
Steroid Receptors
Carcinoid Tumor
Estrogen Receptors
In Situ Hybridization
Blood Proteins
Neoplasms
Proteins
Carcinoma
Messenger RNA

Keywords

  • Age
  • Apocrine
  • Breast carcinoma
  • Hormone receptor
  • Neuroendocrine

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. / Sapino, A.; Righi, L.; Cassoni, P.; Papotti, M.; Gugliotta, P.; Bussolati, G.

In: Modern Pathology, Vol. 14, No. 8, 2001, p. 768-776.

Research output: Contribution to journalArticle

Sapino, A. ; Righi, L. ; Cassoni, P. ; Papotti, M. ; Gugliotta, P. ; Bussolati, G. / Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. In: Modern Pathology. 2001 ; Vol. 14, No. 8. pp. 768-776.
@article{f925ca297f5d42168643503e2c86b60f,
title = "Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women",
abstract = "Neuroendocrine (NE) breast carcinomas are a rare entity in young women; however, their frequency increases in aged patients. The present work demonstrates that NE breast carcinomas in elderly women can also express an apocrine immunophenotype and analyzes the histological and clinical aspects of such differentiation. A selected series of 50 NE tumors (positive for NE markers in ≥50{\%} of the cells) was tested for the immunocytochemical expression of gross cystic disease fluid protein-15 (GCDFP-15). The results demonstrated that about 50{\%} of moderately (G2) and well-differentiated (G1) NE breast carcinomas (mucinous, solid papillary, and solid cohesive histotypes) coexpressed the apocrine marker. In these cases, specific mRNA for GCDFP-15 (PIP) and for chromogranin A (ChA) was demonstrated using in situ hybridization (ISH). Carcinomas of the alveolar subtype (G2) and poorly differentiated carcinomas (G3), including one case of atypical carcinoid, were pure NE carcinomas, devoid of apocrine differentiation. The steroid receptor status of these lesions was evaluated to test a possible involvement of androgen receptors in apocrine differentiation. We demonstrated that the level of AR and the mean age of patients at diagnosis were significantly higher in apocrine than in non-apocrine differentiated tumors. The histological grade and the expression of estrogen receptor (ER) significantly influenced the prognosis of these NE carcinomas, either pure or NE-apocrine differentiated. The most original result of our study is therefore the demonstration of a possible divergent apocrine differentiation of NE breast carcinomas that might be regulated by the activation of androgen receptors in elder patients. In addition, the possibility for using Chs or GCDFP-15 serum values in the follow-up of these patients, as demonstrated in two cases of the present series, can justify the immunophenotyping of the tumors.",
keywords = "Age, Apocrine, Breast carcinoma, Hormone receptor, Neuroendocrine",
author = "A. Sapino and L. Righi and P. Cassoni and M. Papotti and P. Gugliotta and G. Bussolati",
year = "2001",
doi = "10.1038/modpathol.3880387",
language = "English",
volume = "14",
pages = "768--776",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women

AU - Sapino, A.

AU - Righi, L.

AU - Cassoni, P.

AU - Papotti, M.

AU - Gugliotta, P.

AU - Bussolati, G.

PY - 2001

Y1 - 2001

N2 - Neuroendocrine (NE) breast carcinomas are a rare entity in young women; however, their frequency increases in aged patients. The present work demonstrates that NE breast carcinomas in elderly women can also express an apocrine immunophenotype and analyzes the histological and clinical aspects of such differentiation. A selected series of 50 NE tumors (positive for NE markers in ≥50% of the cells) was tested for the immunocytochemical expression of gross cystic disease fluid protein-15 (GCDFP-15). The results demonstrated that about 50% of moderately (G2) and well-differentiated (G1) NE breast carcinomas (mucinous, solid papillary, and solid cohesive histotypes) coexpressed the apocrine marker. In these cases, specific mRNA for GCDFP-15 (PIP) and for chromogranin A (ChA) was demonstrated using in situ hybridization (ISH). Carcinomas of the alveolar subtype (G2) and poorly differentiated carcinomas (G3), including one case of atypical carcinoid, were pure NE carcinomas, devoid of apocrine differentiation. The steroid receptor status of these lesions was evaluated to test a possible involvement of androgen receptors in apocrine differentiation. We demonstrated that the level of AR and the mean age of patients at diagnosis were significantly higher in apocrine than in non-apocrine differentiated tumors. The histological grade and the expression of estrogen receptor (ER) significantly influenced the prognosis of these NE carcinomas, either pure or NE-apocrine differentiated. The most original result of our study is therefore the demonstration of a possible divergent apocrine differentiation of NE breast carcinomas that might be regulated by the activation of androgen receptors in elder patients. In addition, the possibility for using Chs or GCDFP-15 serum values in the follow-up of these patients, as demonstrated in two cases of the present series, can justify the immunophenotyping of the tumors.

AB - Neuroendocrine (NE) breast carcinomas are a rare entity in young women; however, their frequency increases in aged patients. The present work demonstrates that NE breast carcinomas in elderly women can also express an apocrine immunophenotype and analyzes the histological and clinical aspects of such differentiation. A selected series of 50 NE tumors (positive for NE markers in ≥50% of the cells) was tested for the immunocytochemical expression of gross cystic disease fluid protein-15 (GCDFP-15). The results demonstrated that about 50% of moderately (G2) and well-differentiated (G1) NE breast carcinomas (mucinous, solid papillary, and solid cohesive histotypes) coexpressed the apocrine marker. In these cases, specific mRNA for GCDFP-15 (PIP) and for chromogranin A (ChA) was demonstrated using in situ hybridization (ISH). Carcinomas of the alveolar subtype (G2) and poorly differentiated carcinomas (G3), including one case of atypical carcinoid, were pure NE carcinomas, devoid of apocrine differentiation. The steroid receptor status of these lesions was evaluated to test a possible involvement of androgen receptors in apocrine differentiation. We demonstrated that the level of AR and the mean age of patients at diagnosis were significantly higher in apocrine than in non-apocrine differentiated tumors. The histological grade and the expression of estrogen receptor (ER) significantly influenced the prognosis of these NE carcinomas, either pure or NE-apocrine differentiated. The most original result of our study is therefore the demonstration of a possible divergent apocrine differentiation of NE breast carcinomas that might be regulated by the activation of androgen receptors in elder patients. In addition, the possibility for using Chs or GCDFP-15 serum values in the follow-up of these patients, as demonstrated in two cases of the present series, can justify the immunophenotyping of the tumors.

KW - Age

KW - Apocrine

KW - Breast carcinoma

KW - Hormone receptor

KW - Neuroendocrine

UR - http://www.scopus.com/inward/record.url?scp=0035171020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035171020&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3880387

DO - 10.1038/modpathol.3880387

M3 - Article

VL - 14

SP - 768

EP - 776

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 8

ER -